Cantargia (OMX: CANTA)

Currency in SEK

Last close As at 30/11/2023

SEK3.53

−0.05 (−1.40%)

Market capitalisation

SEK657m

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.

Latest Insights

View More

Healthcare | Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare | Flash note

Cantargia — First patient treated in Phase II part of TRIFOUR

Healthcare | Update

Cantargia — Next phase of clinical development in sight

Healthcare | Update

Cantargia — Strong momentum in first nine months of FY22

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net cash (SEKm)

119.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.7 (12.3) 2.3
Relative (8.4) (14.7) (1.1)
52 week high/low SEK9.0/SEK3.0

Financials

Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) for nadunolimab in first-line NSCLC and pancreatic ductal adenocarcinoma (PDAC) support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy, with new encouraging clinical/biomarker data for PDAC reported in September 2023. The company is preparing for a Phase IIb trial in PDAC patients. Further, in October 2023, Cantargia announced positive interim efficacy and safety data from TRIFOUR (Phase Ib/II), assessing nadunolimab in triple-negative breast cancer. Additionally, Cantargia recently announced a $1.1m grant, which will support a new Phase Ib/IIa clinical trial for nadunolimab in leukaemia. A second programme, CAN10, is being developed for the treatment of autoimmune diseases; the company initiated a Phase I trial in September 2023. At end-Q223, Cantargia had a cash and short-term investment position of SEK287.1m.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2021A 0.0 (366.8) (366.5) (365.80) N/A N/A
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023E 0.0 (302.1) (306.6) (183.58) N/A N/A
2024E 0.0 (286.9) (292.6) (175.20) N/A N/A

Research

Flash note

Healthcare

Cantargia — CAN04 progressing on all fronts

Update

Healthcare

Cantargia — Useful insights from CANOPY-1 data

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia: Edison Open House Healthcare 2022

Update

Healthcare

Cantargia — ‘Post-Novartis’ era has begun

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia – executive interview

Flash note

Healthcare

Cantargia — Novartis’s CANOPY-2 trial disappoints

edison tv

Healthcare

Cantargia – Edison Open House interview

Update

Healthcare

Cantargia — Buoyant on CANFOUR and CANOPY interims

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Excellent end to the year

Update

Healthcare

Cantargia — Full Phase I data presented at ASCO

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Nidanilimab transitioning to Phase IIa

Update

Healthcare

Cantargia — CANFOUR interim Phase I presented at ESMO

Update

Healthcare

Cantargia — Phase IIa set to start in Q418

Initiation

Healthcare

Cantargia — Tackling tumour promoting inflammation

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?